Tiziana Life Science Ltd is a biopharmaceutical firm in the clinical stage that develops breakthrough therapies by utilizing transformational drug-delivery technologies.
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
New York, June 9, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery.
Tiziana Life Sciences Announces Positive Clinical Results
In the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab.
NASDAQ:TLSA | LSE:TILS: Foralumab Now in CAR T
On September 2nd, Tiziana Life Sciences PLC (NASDAQ:TLSA) (LSE:TILS) announced an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL) for the exploration and development of foralumab as a lymphodepletion agent to
Tiziana Life Science (TILS.L) TLSA to Host Call to Discuss Exclusive License
Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
Tiziana Life Sciences plc (TILS.L) Posting of Scheme Document and Notice of Meetings
London/New York, 3 September 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Old Tiziana”) a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases
Tiziana Life Science (TILS.L) License Agreement to Evaluate Foralumab with CAR T
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
Tiziana Life Sciences plc (TILS.L) TiLS files scheme for a corporate reorganisation
London/New York, August 20, 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Old Tiziana”) a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases
Tiziana Life Science (TILS.L) Article Publication on Foralumab in COVID Patients
Tiziana Announces Publication of a Peer Reviewed Article on Data from the Clinical Trial with Intranasally Administered Foralumab, Its Proprietary Fully Human Anti-CD3 Monoclonal Antibody, in Mild to Moderate COVID-19
Tiziana Life Science (Nasdaq: TLSA) ADS Ex-Dividend Date Scheduled for July, 09 2021
THIS ANNOUNCEMENT IS FOR US ADS HOLDERS ONLY
Tiziana Life Sciences plc (TILS.L) Distribution Dates for shares and ADRs in Accustem
Distribution Dates for shares and ADRs in Accustem Sciences Limited
Tiziana Life Sci PLC (TILS.L) P2 Trial with foralumab on Severe COVID19 Patients
NEW YORK & LONDON, June 23, 2021 – Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, neurology,